I8F-MC-GPGI - ClinicalTrials.gov - NCT04039503
I8F-MC-GPGI - ClinicalTrials.gov - NCT04039503
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have type 2 diabetes
Participants must have been treated with insulin glargine (U100), once daily with or without metformin ≥3 months
Participants must have hemoglobin A1c ≥7.0% and ≤10.5%
Participants must be of stable weight
Participants must have a BMI ≥23 kilograms per meter squared (kg/m2)
Participants must NOT
Participants must not have type 1 diabetes
Participants must not have pancreatitis
Participants must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
Participants must not have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
Participants must not have been taking weight loss drugs, including over-the-counter medications during the last 3 months
Trial Summary
Conditions the trial is for
Adult Type 2 Diabetes
What the trial is testing?
Tirzepatide, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
472
Trial Dates
August 2019 - January 2021
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have type 2 diabetes
Participants must have been treated with insulin glargine (U100), once daily with or without metformin ≥3 months
Participants must have hemoglobin A1c ≥7.0% and ≤10.5%
Participants must be of stable weight
Participants must have a BMI ≥23 kilograms per meter squared (kg/m2)
Participants must NOT
Participants must not have type 1 diabetes
Participants must not have pancreatitis
Participants must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
Participants must not have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
Participants must not have been taking weight loss drugs, including over-the-counter medications during the last 3 months
Trial Summary
Conditions the trial is for
Adult Type 2 Diabetes
What the trial is testing?
Tirzepatide, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
472
Trial Dates
August 2019 - January 2021
Trial Phase
3
Trial Locations
Hide locations not currently recruiting